j-alex trial: should alecensa replace xalkori as first-line alk therapy?
Published 7 years ago • 809 plays • Length 11:02Download video MP4
Download video MP3
Similar videos
-
6:33
a practice change for alk lung cancer patients, alecensa for first line treatment
-
4:14
should a second generation alk inhibitor be first line therapy for patients with alk-positive nsclc?
-
4:58
how do the new alk inhibitor drugs compare to xalkori (crizotinib) for alk lung cancer patients?
-
2:20
timing of second generation alk inhibitors: first line vs. treatment after acquired resistance
-
2:15
new alk inhibitor drugs vs xalkori (crizotinib) for alk lung cancer patients
-
5:52
alk positive forum disease progression xalkori
-
22:46
mechanisms of alk resistance & implications for treatment
-
4:27
alk positive lung cancer forum: xalkori
-
3:44
alk inhibitors for acquired resistance: zykadia and alectinib
-
4:43
phase 3 alex study: comparing alecensa to xalkori in alk lung cancer
-
37:41
gracecast-044_lung-cancer_camidge on alk inhibitors
-
4:44
are there clinically significant differences among the second generation alk inhibitors?
-
0:45
slcvl - hunis - #12 second line therapy for nsclc and alk
-
1:47
alk rearrangements: what are they, and who has them?
-
17:30
gracecast-084_lung-cancer_alk inhibition: science and early clinical experience by dr. ben solomon
-
5:42
gracecast - lcvl- what are the options after a patient with an alk-positive advanced nsclc develops
-
2:39
grace targeted therapies lung cancer 2021 - return to alectinib -progression on lorlatinib in alk
-
26:56
gracecast-085_lung-cancer_alk inhibition: who to screen and options for alk-positive patients
-
3:12
q&a: new lesions - switch from alectinib to lorlatinib? targeted therapies in lung cancer 2023